Cargando…

VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2

Triple-negative breast cancer (TNBC) and its recently identified subtype, quadruple negative breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer cases in the United States. These aggressive forms of breast cancer are associated with poor prognoses, limited trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Thankan, Retheesh S., Thomas, Elizabeth, Purushottamachar, Puranik, Weber, David J., Ramamurthy, Vidya P., Huang, Weiliang, Kane, Maureen A., Njar, Vincent C. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520556/
https://www.ncbi.nlm.nih.gov/pubmed/37766871
http://dx.doi.org/10.3389/fonc.2023.1240996
_version_ 1785109946428293120
author Thankan, Retheesh S.
Thomas, Elizabeth
Purushottamachar, Puranik
Weber, David J.
Ramamurthy, Vidya P.
Huang, Weiliang
Kane, Maureen A.
Njar, Vincent C. O.
author_facet Thankan, Retheesh S.
Thomas, Elizabeth
Purushottamachar, Puranik
Weber, David J.
Ramamurthy, Vidya P.
Huang, Weiliang
Kane, Maureen A.
Njar, Vincent C. O.
author_sort Thankan, Retheesh S.
collection PubMed
description Triple-negative breast cancer (TNBC) and its recently identified subtype, quadruple negative breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer cases in the United States. These aggressive forms of breast cancer are associated with poor prognoses, limited treatment options, and lower overall survival rates. In previous studies, our research demonstrated that VNLG-152R exhibits inhibitory effects on TNBC cells both in vitro and in vivo and the deuterated analogs were more potent inhibitors of TNBC cells in vitro. Building upon these findings, our current study delves into the molecular mechanisms underlying this inhibitory action. Through transcriptome and proteome analyses, we discovered that VNLG-152R upregulates the expression of E3 ligase Synoviolin 1 (SYVN1), also called 3-hydroxy-3-methylglutaryl reductase degradation (HRD1) in TNBC cells. Moreover, we provide genetic and pharmacological evidence to demonstrate that SYVN1 mediates the ubiquitination and subsequent proteasomal degradation of MNK1/2, the only known kinases responsible for phosphorylating eIF4E. Phosphorylation of eIF4E being a rate-limiting step in the formation of the eIF4F translation initiation complex, the degradation of MNK1/2 by VNLG-152R and its analogs impedes dysregulated translation in TNBC cells, resulting in the inhibition of tumor growth. Importantly, our findings were validated in vivo using TNBC xenograft models derived from MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines, representing different racial origins and genetic backgrounds. These xenograft models, which encompass TNBCs with varying androgen receptor (AR) expression levels, were effectively inhibited by oral administration of VNLG-152R and its deuterated analogs in NRG mice. Importantly, in direct comparison, our compounds are more effective than enzalutamide and docetaxel in achieving tumor growth inhibition/repression in the AR+ MDA-MD-453 xenograft model in mice. Collectively, our study sheds light on the involvement of SYVN1 E3 ligase in the VNLG-152R-induced degradation of MNK1/2 and the therapeutic potential of VNLG-152R and its more potent deuterated analogs as promising agents for the treatment of TNBC across diverse patient populations.
format Online
Article
Text
id pubmed-10520556
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105205562023-09-27 VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2 Thankan, Retheesh S. Thomas, Elizabeth Purushottamachar, Puranik Weber, David J. Ramamurthy, Vidya P. Huang, Weiliang Kane, Maureen A. Njar, Vincent C. O. Front Oncol Oncology Triple-negative breast cancer (TNBC) and its recently identified subtype, quadruple negative breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer cases in the United States. These aggressive forms of breast cancer are associated with poor prognoses, limited treatment options, and lower overall survival rates. In previous studies, our research demonstrated that VNLG-152R exhibits inhibitory effects on TNBC cells both in vitro and in vivo and the deuterated analogs were more potent inhibitors of TNBC cells in vitro. Building upon these findings, our current study delves into the molecular mechanisms underlying this inhibitory action. Through transcriptome and proteome analyses, we discovered that VNLG-152R upregulates the expression of E3 ligase Synoviolin 1 (SYVN1), also called 3-hydroxy-3-methylglutaryl reductase degradation (HRD1) in TNBC cells. Moreover, we provide genetic and pharmacological evidence to demonstrate that SYVN1 mediates the ubiquitination and subsequent proteasomal degradation of MNK1/2, the only known kinases responsible for phosphorylating eIF4E. Phosphorylation of eIF4E being a rate-limiting step in the formation of the eIF4F translation initiation complex, the degradation of MNK1/2 by VNLG-152R and its analogs impedes dysregulated translation in TNBC cells, resulting in the inhibition of tumor growth. Importantly, our findings were validated in vivo using TNBC xenograft models derived from MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines, representing different racial origins and genetic backgrounds. These xenograft models, which encompass TNBCs with varying androgen receptor (AR) expression levels, were effectively inhibited by oral administration of VNLG-152R and its deuterated analogs in NRG mice. Importantly, in direct comparison, our compounds are more effective than enzalutamide and docetaxel in achieving tumor growth inhibition/repression in the AR+ MDA-MD-453 xenograft model in mice. Collectively, our study sheds light on the involvement of SYVN1 E3 ligase in the VNLG-152R-induced degradation of MNK1/2 and the therapeutic potential of VNLG-152R and its more potent deuterated analogs as promising agents for the treatment of TNBC across diverse patient populations. Frontiers Media S.A. 2023-09-11 /pmc/articles/PMC10520556/ /pubmed/37766871 http://dx.doi.org/10.3389/fonc.2023.1240996 Text en Copyright © 2023 Thankan, Thomas, Purushottamachar, Weber, Ramamurthy, Huang, Kane and Njar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Thankan, Retheesh S.
Thomas, Elizabeth
Purushottamachar, Puranik
Weber, David J.
Ramamurthy, Vidya P.
Huang, Weiliang
Kane, Maureen A.
Njar, Vincent C. O.
VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title_full VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title_fullStr VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title_full_unstemmed VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title_short VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2
title_sort vnlg-152r and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating e3 ligase synoviolin 1 (syvn1) and inducing proteasomal degradation of mnk1/2
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520556/
https://www.ncbi.nlm.nih.gov/pubmed/37766871
http://dx.doi.org/10.3389/fonc.2023.1240996
work_keys_str_mv AT thankanretheeshs vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT thomaselizabeth vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT purushottamacharpuranik vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT weberdavidj vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT ramamurthyvidyap vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT huangweiliang vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT kanemaureena vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12
AT njarvincentco vnlg152randitsdeuteratedanalogspotentlyinhibitrepresstriplequadruplenegativebreastcancerofdiverseracialoriginsinvitroandinvivobyupregulatinge3ligasesynoviolin1syvn1andinducingproteasomaldegradationofmnk12